This is Why Disc Medicine, Inc. (IRON) is a Buy on Wall Street

Disc Medicine, Inc. (NASDAQ:IRON) is one of the best 52-week high stocks to buy right now. On November 20, analysts at Jefferies reiterated a Buy rating on the stock with a $127 price target. The research firm has echoed the company’s strong performance and continued momentum in 2026. It expects the momentum to be driven by the bitopertin approval as a treatment option for erythropoietic protoporphyria (EPP) and its potential launch early next year.

The company is staring at a tremendous opportunity following the Confirmed Pediatric Investigation Plan Verification (CNPV), which underscores unmet need around erythropoietic protoporphyria (EPP). Upcoming Phase 2 interim data for DISC-0974 in anemia myelofibrosis (MF) is also a potential catalyst.

Meanwhile, TD Cowen analyst Tara Bancroft reiterated a Buy rating on the stock on November 14, impressed by the promising outlook for bitopertin, a first-in-class treatment for erythropoietic protoporphyria (EPP). The drug is poised to capture significant market potential valued at $700 million.

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes new treatments for serious hematologic diseases, such as those affecting red blood cells and iron metabolism. They focus on building a pipeline of therapies that target fundamental biological pathways, including heme biosynthesis and iron homeostasis, to help patients with conditions like erythropoietic protoporphyria (EPP).

While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.